Resources
Proteomics Databases
Metabolomics Databases

-
• Bottom-Up vs. Top-Down Proteomics: How to Choose the Right Strategy for Protein Characterization
Compare bottom-up and top-down proteomics for protein characterization by structural resolution, sample complexity, proteoform context, and decision criteria for biologics QC and comparability.
-
• Bottom-Up Proteomics: Workflow, LC-MS/MS Principles, and Applications in Protein Analysis
Learn bottom-up proteomics workflow, LC-MS/MS principles, and protein analysis applications for identification, quantitation, PTM mapping, and biologics characterization.
-
• Bottom-Up Proteomics: Principles, Workflow, and Analysis
Learn bottom-up proteomics principles, standard workflow steps, and analysis pipeline design for peptide identification, protein inference, and quantification.
-
• Basics of Protein and Antibody Glycosylation
Learn the basics of protein and antibody glycosylation, including N-linked and O-linked structures, analytical methods, and applications in biopharmaceutical characterization.
-
• Antibody Glycosylation in Inflammation, Disease and Vaccination
Explore antibody glycosylation in inflammation, disease, and vaccination, including IgG Fc glycan shifts, effector modulation, vaccine response maturation, and glycan profiling in immune research.
-
• Antibody Glycosylation in Autoimmune Diseases
Learn how antibody glycosylation influences autoimmune disease activity, effector function, and IgG effector profiles in rheumatoid arthritis, lupus, and related conditions.
-
Learn antibody glycosylation analysis methods, workflow, and applications in biotherapeutic characterization, including released N-glycan profiling, glycopeptide LC-MS/MS, comparability, and biosimilar support.
-
• N-Terminal Sequencing: Approaches for Confirming Mature Protein Starts and Processing Sites
Many proteins do not begin with the first residue encoded in the gene. Signal peptides are removed during secretion. Propeptides may be cleaved before the mature form becomes active. Recombinant expression systems can leave unintended N-terminal extensions or fail to remove leader sequences as expected. In each case, the biologically relevant question is not only what the gene encodes, but where the mature protein actually starts.
-
• Scoping N-Terminal Sequencing for Release Testing: Read Length, Sample Format, and Deliverables
N-terminal sequencing projects move faster when scope is defined before samples ship. Teams often request a fixed read length without confirming whether the material supports that depth, whether the N-terminus is accessible, or whether the final report must satisfy internal QC, regulatory documentation, or publication standards. Unclear scope leads to repeated runs, extended timelines, and reports that do not match the decision the project team actually needs to make.
-
• N-Terminal Sequencing Routes Compared: Edman Degradation, MS Analysis, and Peptide Mapping for QC
N-terminal QC projects rarely fail because teams lack analytical capability. They fail because the selected route does not match the sample chemistry or the evidence standard required for the next decision. One team may need a direct ten-residue N-terminal read for lot release. Another may need to characterize a blocked recombinant terminus. A third may only need confirmation that processing removed a signal peptide correctly when a full reference sequence already exists.
How to order?
